Daily Stock Analysis, AQXP, Aquinox Pharmaceuticals Inc, priceseries

Aquinox Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
0.00
Close
0.00
High
0.00
Low
0.00
Previous Close
0.00
Daily Price Gain
0.00
YTD High
0.00
YTD High Date
Wrong Month 0, 0
YTD Low
0.00
YTD Low Date
Wrong Month 0, 0
YTD Price Change
0.00
YTD Gain
-nan%
52 Week High
0.00
52 Week High Date
Wrong Month 0, 0
52 Week Low
0.00
52 Week Low Date
Wrong Month 0, 0
52 Week Price Change
0.00
52 Week Gain
-nan%
Company Information
Stock Symbol
AQXP
Exchange
NasdaqGM
Company URL
http://www.aqxpharma.com
Company Phone
604-629-9223
CEO
David J. Main
Headquarters
British Columbia
Business Address
887 GREAT NORTHERN WAY, SUITE 450, VANCOUVER, CANADA V5T 4T5
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001404644
About

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. The company's primary focus is on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox Pharmaceuticals was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong and Gerald Krysta on December 26, 2003 and is headquartered in Vancouver, Canada.

Description

Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The company primarily focuses on anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1 (SHIP1) enzyme, a key regulator of a cellular signaling pathway in immune cells. Its lead product candidate is AQX-1125, a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome, a chronic inflammatory disease of the bladder. The company was founded in 2003 and is headquartered in Vancouver, Canada.